Unraveling Epigenetic Modifications in Glaucoma: Biomarkers and Therapeutic Targets

Epigenetic alterations have a crucial role in neurodegenerative disorders and aging, providing valuable information about the regulation of genes and the cellular mechanisms that influence the evolution of these diseases. They play a role in various areas of pathogenesis, such as inflammation, neuronal metabolism, proteostasis, and cell death, in neurodegenerative disorders like Alzheimer, Parkinson, amyotrophic lateral sclerosis, and glaucoma. Epigenetic modifications, which contribute to the susceptibility to neurodegenerative illnesses, are a manifestation of the aging process, which is a substantial risk factor for these diseases. Research emphasizes the identification of diagnostic biomarkers, pathways, and therapeutic targets, which can lead to the development of new techniques for prevention and treatment. Epigenetics plays a role in the natural aging process and provides insights for developing therapies to slow down or reverse aging. Glaucoma, a neurological illness with several factors, is a major cause of permanent blindness globally. Although there have been significant improvements in comprehending the causes and treatment of the condition, identifying it at an early stage and providing appropriate medical care still pose difficulties. Epigenetic alterations, such as DNA methylation, histone modifications, and noncoding RNAs, are important regulators of gene expression and cellular functions. This chapter focuses on the significance of epigenetics in understanding the genetic and molecular complexities of glaucoma. It provides an overview of the disease’s pathogenesis, with a particular emphasis on the regulation of intraocular pressure, dysfunction of retinal ganglion cells, and intricacy of optic nerve injury. This study investigates the impact of epigenetic alterations on gene expression, specifically in relation to glaucomatous neurodegeneration and its contribution to the development of glaucoma. The text discusses evidence from both animal models and human investigations, providing insights into the epigenetic changes that are linked to the development and advancement of glaucoma. Furthermore, the discussion revolves around the possibility of using epigenetic modifications as diagnostic indicators and therapeutic targets for personalized and accurate glaucoma treatment.